Myeloma Cells
Myeloma Cells - Related Videos
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
0 Views •
Cited by 29 •
2015
We describe a high-throughput drug sensitivity assay for primary multiple myeloma cells. It consists of a reconstruction of the bone marrow microenvironment (including extracellular matrix and stroma) in multi-well plates, and a non-invasive method for longitudinal quantification of cell viability.
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
0 Views •
Cited by 16 •
2015
Human multiple myeloma (MM) cells require the supportive microenvironment of mesenchymal cells and extracellular matrix components for survival and proliferation. We established an in vivo chicken embryo model with engrafted human myeloma and mesenchymal cells to study effects of cancer drugs on tumor growth, invasion and angiogenesis.
07:53
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
0 Views •
Cited by 2 •
2022
Here, we present a protocol for improving the success of interphase fluorescence in situ hybridization detection on bone marrow smears from multiple myeloma patients.
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
0 Views •
Cited by 17 •
2018
This manuscript describes the synthesis of a single-wall carbon nanotube (SWCNT)-conjugated MALAT1 antisense gapmer DNA oligonucleotide (SWCNT-anti-MALAT1), which demonstrates the reliable delivery of the SWCNT and the potent therapeutic effect of anti-MALAT1 in vitro and in vivo. Methods used for synthesis, modification, conjugation, and injection of SWCNT-anti-MALAT1 are described.
05:32
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
0 Views •
Cited by 3 •
2019
Here we use bioluminescent, X-ray, and positron-emission tomography/computed tomography imaging to study how inhibiting mTOR activity impacts bone marrow-engrafted myeloma tumors in a xenograft model. This allows for physiologically relevant, non-invasive, and multimodal analyses of the anti-myeloma effect of therapies targeting bone marrow-engrafted myeloma tumors in vivo.
FAQs
Genetic changes can give myeloma cells a growth advantage, allowing proliferation that no longer follows normal controls. In the bone marrow, this expansion can interfere with the production of other blood-cell types. The biological consequence is therefore broader than tumor growth alone: it links altered cell regulation to anemia and other disruptions of normal blood formation.
Large-scale production of one immunoglobulin or immunoglobulin fragment is an important biological readout of myeloma-cell activity. It distinguishes the abnormal plasma-cell population from the broader immune response and gives researchers a way to study how plasma-cell development becomes linked to cancer and immune-system dysfunction as a disease-related process.
Expansion in bone marrow affects more than the myeloma cells themselves. By disrupting normal blood-cell production, the disease process can contribute to anemia, while associated bone damage reflects effects on skeletal tissue. Impaired immunity adds a separate consequence, showing that myeloma-cell biology connects abnormal growth, tissue injury, and reduced immune protection.
To create a hybridoma, researchers fuse a selected immortal myeloma cell line with an antibody-producing B cell. The fusion combines the capacity for continued growth associated with the myeloma cell with antibody production from the B cell. Resulting hybridomas can provide a stable source of one monoclonal antibody for laboratory or clinical applications.
Their value comes from their use as a fusion partner rather than simply as a disease model. When combined with an antibody-producing B cell, an immortal myeloma line helps generate a hybridoma capable of sustained monoclonal antibody production. This makes the resulting cell system useful when a stable and reproducible antibody source is required.
Biologists study myeloma cells in two connected contexts. As malignant plasma cells, they support research on plasma-cell development, cancer mechanisms, bone-marrow disruption, and immune dysfunction. As components of hybridomas, selected immortal lines support production of monoclonal antibodies used in research, diagnosis, and therapy. The same topic therefore links disease biology with biotechnology.